Edgewise Therapeutics Inc. Common Stock vs Kyndryl Holdings Inc — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.11 (market cap $3.94B), while Kyndryl Holdings Inc trades at $11.78 (market cap $2.67B). The key difference: Edgewise Therapeutics Inc. Common Stock is the larger of the two by market cap, and Edgewise Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Kyndryl Holdings Inc for 36 Days on average.
| EWTX | KD | |
|---|---|---|
Market Cap | $3.94B | $2.67B |
Volume | 810,104 | 3,966,787 |
Sector | Health | Technology |
52-Week High | $48.35 | $28.92 |
52-Week Low | $14.89 | $10.59 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $3.48B | $5.49B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kyndryl (KD) trades at $11.79, up slightly by 0.08% with neutral technical indicators. The company shows improving fundamentals with 2025 revenue of $15.06B and a return to profitability with $252M net income after three years of losses. Recent earnings have been mixed with two misses and one beat. Analyst consensus is cautious with 71% hold ratings, though the $14.67 price target suggests 24% upside potential from current levels.
The stock presents a turnaround story with improving cash flow and profitability, but faces execution risks amid competitive pressures. Recent AI-focused initiatives and government contracts provide growth catalysts, though the high P/E ratio of 33.08 requires strong earnings growth to justify valuation. Institutional ownership trends and technical resistance near $12 remain key watchpoints.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →